Project Grant HT94252310685

This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...

The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...

This $653,317 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of a novel graft-localized drug delivery platform at Wake Forest University Health Sciences (WFUHS). The funding will be used to conduct research aimed at attenuating innate inflammation and optimizing immunosuppression in vascularized composite allotransplantation over a 2-year period from September 2024 to September 2026. WFUHS, a leading...

The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...

The Defense Health Agency awarded Duke University a $483,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of March 1, 2021 through February 28, 2024. The grant funding will support Duke University's research project "Targeting Glutamine Utilization in Therapy-Resistant Prostate Cancer." The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research...

The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...

This $299,999 Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by Wake Forest University Health Sciences (WFUHS) to develop microparticle delivery of chemokine muteins for guiding chemokine receptor engineered regulatory T cells (Tregs) to induce tolerance after vascular composite allograft transplants. The research project aims to advance therapeutic...

The Defense Health Agency awarded Duke University a $804,999 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research on "DETECTING MISSED METASTASES FROM NOMINALLY EARLY-STAGE MELANOMAS WITH PUMP-PROBE MICROSCOPY". The award runs from September 1, 2023 to August 31, 2026. The Project Grant enables Duke's research to transform health care for Service Members and the American public through innovative and impactful biomedical research...

The Defense Health Agency awarded a $899,999 Project Grant to Wake Forest University Health Sciences under the Military Medical Research and Development program (CFDA 12.420) to develop a novel point-of-care assay for monitoring rejection and immunosuppression in vascularized composite allotransplantation (VCA) recipients. The project aims to transform healthcare for service members and the public through innovative biomedical research focused on medical solutions for the battlefield. The...

The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...